Tecartus
FDA Eliminates REMS for 6 CAR T-Cell Immunotherapies
The FDA announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for six currently approved ...
JULY 8, 2025
Anti-CD19 CAR T-Cell Therapy Shows Efficacy in R/R B-Cell ALL in Adults
A single infusion of anti-CD19 chimeric antigen receptor T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) ...
SEPTEMBER 22, 2021
Tecartus Approved as First CAR T-Cell Therapy for Mantle Cell Lymphoma
The FDA approved the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) for ...
JULY 28, 2020
Load more